RANZCOG CREI Consensus Statement on treatment of Ovarian Hyperstimulation Syndrome

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 55, Issue 5, 2015, Pages 413-419

  Kwik, Michele ^a,b,c   Karia, Sonal ^d   Boothroyd, Clare ^e  

^a IVFAustralia   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Genea   (Australia)

^e GREENSLOPES PRIVATE HOSPITAL   (Australia)

Author keywords

hyperstimulation; ovarian; syndrome; treatment

Indexed keywords

ANTIHISTAMINIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT;

ADJUVANT THERAPY; ARTICLE; CONSENSUS DEVELOPMENT; EVIDENCE BASED PRACTICE; FEMALE; FLUID RESUSCITATION; GOOD CLINICAL PRACTICE; HEALTH EDUCATION; HOSPITAL PATIENT; HUMAN; LOW DRUG DOSE; OUTPATIENT CARE; OUTPATIENT DEPARTMENT; OVARY HYPERSTIMULATION; OXYGEN SATURATION; PARACENTESIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; THROMBOSIS PREVENTION; ADVERSE EFFECTS; CONSENSUS; EVIDENCE BASED MEDICINE; META ANALYSIS; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PRACTICE GUIDELINE; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TREATMENT OUTCOME;

CONSENSUS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84942984928     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/ajo.12389     Document Type: Article

References (42)

1. Schenker JG, Weinstein D,. Ovarian hyperstimulation syndrome: a current survey. Fertil Steril 1978; 30: 255-268.
2. Macaldowie A, Wang YA, Chambers GM, Sullivan EA, 2013. Assisted Reproductive Technology in Australia and New Zealand 2011. Sydney: National Perinatal Epidemiology and Statistics Unit, the University of New South Wales.
3. The management of Ovarian Hyperstimulation Syndrome. A Green-top Guideline. London: RCOG press at the Royal College of Obstetricians and Gynaecologists, 2006.
4. Tan BK, Mathur R,. Management of ovarian hyperstimulation syndrome. Produced on behalf of the BFS policy and practice committee. Human Fertility 2013; 16 (3): 151-159.
5. The Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril 2008; 90 (supp3): S188-S192.
6. Golan A, Weissman A,. A modern classification of OHSS. Reprod Biomed Online 2009; 19: 28-32.
7. Rizk B, Aboulghar M,. Modern management of ovarian hyperstimulation syndrome. Hum Reprod 1991; 6: 1082-1087.
8. Humaidan P, Quartarolo J, Papanikolaou EG,. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril 2010; 94: 389-400.
9. Navot D, Bergh PA, Laufer N,. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992; 58: 249-261.
10. Pride SM, Yuen BH, Moon YS, Leung PC,. Relationship of gonadotropin-releasing hormone, danazol, and prostaglandin blockade to ovarian enlargement and ascites formation of the ovarian hyperstimulation syndrome in the rabbit. Am J Obstet Gynecol 1986; 154: 1155-1160.
11. Borenstein R, Elhalah U, Lunenfeld B, Schwartz ZS,. Severe ovarian hyperstimulation syndrome: a reevaluated therapeutic approach. Fertil Steril 1989; 51: 791-795.
12. Navot D, Margalioth EJ, Laufer N, et al., Direct correlation between plasma rennin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril 1987; 48: 57-61.
13. Binder H, Dittrich R, Einhaus F, et al., Update on ovarian hyperstimulation syndrome: part 1- incidence and pathogenesis. Int J Fertil Womens Med 2007; 52: 11-26.
14. Avecillas JF, Falcone T, Arroliga AC,. Ovarian hyperstimulation syndrome. Crit Care Clin 2004; 20 (4): 679-695.
15. Budev MM, Arroliga AC, Falcone T,. Ovarian hyperstimulation syndrome. Crit Care Med 2005; 33 (10suppl): S301-S306.
16. Abuzeid MI, Nassar Z, Massaad Z, et al., Pigtail catheter for the treatment of ascites associated with ovarian hyperstimulation syndrome. Hum Reprod 2003; 18: 370-373.
17. Smith LP, Hacker MR, Alper MM,. Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis. Fert Steril 2009; 92: 1953-1959.
18. Shrivastav P, Nadkarni P, Craft I,. Day care management of severe ovarian hyperstimulation syndrome avoids hospitalization and morbidity. Hum Reprod 1994; 9: 812-814.
19. Ozgun MT, Batukan C, Oner G, et al., Removal of ascites up to 7.5 liters on one occasion and 45 liters in total may be safe in patients with severe ovarian hyperstimulation syndrome. Gynecol Endocrinol 2008; 24: 656-658.
20. Chen CD, Yang JH, Chao KH, et al., Effects of repeated abdominal paracentesis on uterine and intraovarian haemodynamics and pregnancy outcome in severe ovarian hyperstimulation syndrome. Hum Reprod 1998; 13: 2077-2081.
21. Manno M, Tomei F, Marchesan E, Adamo V,. Cabergoline: a safe, easy, cheap and effective drug for prevention/treatment of ovarian hyperstimulation syndrome? Eur J Obstet Gynecol Reprod Biol 2005; 122: 127.
22. Rollene NL, Amols MH, Hudson SBA, Coddington CC,. Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series. Fertil Steril 2009; 92: 1169.e15-1169.e17.
23. Ata B, Seyhan A, Orhaner S, Urman B,. High dose cabergoline in management of ovarian hyperstimulation syndrome. Fertil Steril 2009; 92: 1168.e1-1168.e4.
24. Ferraretti AP, Gianaroli L, Diotallevi L, et al., Dopamine treatment for severe ovarian hyperstimulation syndrome. Hum Reprod 1992; 7: 180-183.
25. Tsunoda T, Shibahara H, Hirano Y, et al., Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamine. J Gynaecol Endocrinol 2003; 17: 281-286.
26. Ricci E, Parazzini F, Motta T, et al., Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 2002; 16: 791-793.
27. Hurault-Delarue C, Montastruc JL, Beau AB, et al., Pregnancy outcome in women exposed to dopamine agonists during pregnancy: a pharmacoepidemiology study in EFEMERIS database. Arch Gynecol Obstet 2014; 290: 263-270.
28. Stalldecker G, Mallea-Gil MS, Guitelman M, et al., Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary 2010; 13: 345-350.
29. McElhinney B, McClure N,. Ovarian hyperstimulation syndrome. Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14: 103-122.
30. Whelan JG III, Vlahos NF,. The ovarian hyperstimulation syndrome. Fertil Steril 2000; 73: 883-896.
31. Fleming T, Sacks G, Nasser J,. Internal jugular vein thrombosis following ovarian hyperstimulation syndrome. Aust N Z J Obstet Gynaecol 2012; 52: 87-90.
32. Aboulghar MA, Mansour RT, Serour GI, et al., Management of severe ovarian hyperstimulation syndrome by ascetic fluid aspiration and intensive intravenous fluid therapy. Obstet Gynecol 1998; 81: 108-111.
33. Qublan HS, Al-Taani MI, Megdadi MF, et al., Multiple transvaginal ascitic fluid aspirations improves the clinical and reproductive outcome in patients undergoing in vitro fertilisation treatment complicated by severe early ovarian hyperstimulation syndrome. J Obstet Gynecol 2012; 32: 379-382.
34. Takamizawa S, Shibahara H, Taneichi A, et al., Dynamic changes of the immunoglobulins in patients with severe ovarian hyperstimulation syndrome: efficacy of a novel treatment using peritoneo-venous shunt. Am J Reprod Immunol 2002; 47: 25-30.
35. Aboulghar MA, Mansour RT, Serour GI, et al., Autotransfusion of the ascitic fluid in the treatment of severe ovarian hyperstimulation syndrome. Fertil Steril 1992; 58: 1056-1059.
36. Zosmer A, Katz Z, Lancet M, et al., Adult respiratory distress syndrome complicating ovarian hyperstimulation syndrome. Fertil Steril 1987; 47 (3): 524-526.
37. Chen CD, Chen SU, Yang YS,. Prevention and management of ovarian hyperstimulation syndrome. Best Pract Clin Obstet Gynaecol 2012; 26: 817-827.
38. Balasch J, Fabregues F, Arroyo V, et al., Treatment of severe ovarian hyperstimulation syndrome by a conservative medical approach. Acta Obstet Gynecol Scand 1996; 75: 662-667.
39. Thaler I, Yoffe N, Kaftory JK, Brandes JM,. Treatment of ovarian hyperstimulation syndrome: the physiologic basis for a modified approach. Fertil Steril 1981; 36: 110-113.
40. Ando H, Furugori K, Shibata D, et al., Dual renin-angiotensin blockade therapy in patients at high risk of early ovarian hyperstimulation syndrome receiving IVF and elective embryo cryopreservation: a case series. Hum Reprod 2003; 18: 1219-1222.
41. Bergh PA, Navot D,. Ovarian hyperstimulation syndrome: a review of pathophysiology. J Assist Reprod Genet 1992; 9: 429-438.
42. Lainas GT, Kolibianakis EM, Sfontouris IA, et al., Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome. BJOG 2014; 121: 848-855.